+3 C°
Traffic jam:   0

Johnson & Johnson's COVID -19 vaccine receives FDA approval

1 March 2021
2 min.
Johnson & Johnson's COVID -19 vaccine receives FDA approval

FDA approves vaccine

Johnson&Johnson has received approval for emergency use of its vaccine in the US, with the advantages of single-dose administration and standard storage requirements.

Johnson&Johnson received official US Food and Drug Administration (FDA) approval on Saturday for emergency use of its COVID-19 vaccine within the country.

Shares in Johnson&Johnson, up almost 14% in the past 12 months, were up 3.52% before trading opened on Monday.

J&J earlier said it plans to deliver 20 million doses of its vaccine by the end of March from a government contract to deliver 100 million doses by the end of June.

Although Pfizer and BioNTech as well as Moderna are ahead of J&J in starting deliveries of coronavirus vaccines, J&J's vaccine has an advantage over them as it creates high immunity against coronavirus when administered once, without requiring repeat vaccination. The level of protection of the J&J vaccine varied by region: the average efficacy was 66%, among those tested in the USA the efficacy was 72%, 66% in Latin America and 57% in South Africa. However, after about a month, the effectiveness of the vaccine in South Africa had risen to 64%.

According to a press release from J&J, its vaccine proved effective against the new, more infectious strain of the SARS-CoV-2 B.1.351 coronavirus that is prevalent in South Africa.

Pfizer and Moderna vaccines had 95% and 94% efficacy, respectively, but these data did not include testing of the new coronavirus strains. These companies are currently conducting further research.

According to the company, the J&J vaccine prevented 100% of hospital admissions and deaths among 43,783 test participants aged 18 and over, and met the FDA's minimum requirement of 50% vaccine efficacy. Johnson&Johnson executives have previously stated that the company will not make any money from the vaccines during a pandemic, they will be made available "on a non-commercial basis for emergency use".

J&J could profit from vaccines against COVID-19 if such vaccination is included in the annual mandatory vaccination calendar in the US and other countries.

Companies5 in the news



Rating companies
52 Mention
51 Mention
49 Mention
46 Mention
Dow Jones
40 Mention
38 Mention
White House
31 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director